Saturday, August 29, 2026

The U.S. Prescription Drug Market Has Changed, But Our Assumptions About It Did Not

›
The way Americans buy prescription drugs has changed so much that many of the old assumptions we still rely on now have potential to work ag...
Tuesday, August 11, 2026

Breakthrough T1D's coup d'état of the T1D Fund's Board

›
Remember back in 2021 when the New York Times (see the article at https://www.nytimes.com/2021/07/02/your-money/philanthropy-type-1-diabete...
Monday, August 03, 2026

Meitheal Pharmaceuticals Announces FDA Approval of Garzulys™ (insulin aspart-fsan), Becoming the 3rd Insulin Aspart Biosimilar Approved in 2026

›
On July 24, 2026, there was news that Chicago-based Meitheal Pharmaceuticals had received FDA approval for another (the third approved in 20...
Wednesday, June 10, 2026

The Most Lucrative Biosimilar Insulin Opportunity May Not Be the Biggest One

›
The race to develop biosimilar or follow-on biologic entrants in the U.S. insulin market has suffered from a fundamental strategic flaw: cha...
Tuesday, May 12, 2026

With UNH's Optum Rx Reforms, The Last Big PBM Domino Is Falling

›
Bloomberg health care reporter John Tozzi reported on LinkedIn (the link he shared is at https://www.bloomberg.com/news/articles/2026-05-11...
Monday, May 04, 2026

FDA Approves Yet Another Glargine Insulin Biosimilar from Lannett Company/HEC

›
Today, there was a press release (see  https://www.businesswire.com/news/home/20260504761789/en/Lannett-Company-Lanexa-Biologics-and-Sunshin...
Monday, April 06, 2026

PBM Formulary Exclusions Are Going Away, Ending "Not Covered" By Your Insurance

›
For years, people with Type 1 diabetes in the United States have been told some version of the same thing at the pharmacy counter: that'...
Thursday, March 19, 2026

Unbranded Humalog Is Cheap on TrumpRx—And GoodRx Enables It.

›
  Back on January 27, 2026, the Office of Inspector General ("OIG") for the U.S. Department of Health and Human Services ("HH...